赢博娱乐网页版手机版登录

郑小虎

Special Professor

Supervisor of Doctorate Candidates

Supervisor of Master's Candidates

E-Mail:

Education Level:With Certificate of Graduation for Doctorate Study

Business Address:赢博娱乐网页版手机版登录西校区医算楼1604

Degree:Dr

Alma Mater:赢博娱乐网页版手机版登录

Discipline:Biology

Academic Honor

2021 National Excellent Green

Honors and Titles

2025-01-07 安徽省科学技术奖一等奖

2021-08-06 中国免疫学会青年学者奖

2015-08-06 中国科赢博娱乐网页版手机版登录院长奖

Recommended Ph.D.Supervisor>>
Recommended MA Supervisor>>

mobiles Version

Click:Times

The Last Update Time: ..

Home
Scientific Research
Teaching Research
Awards and Honours
Enrollment Information
Student Information
My Album
Blog

Current position: Home >> Scientific Research >> Paper Publications

Paper Publications

[11] Jiacheng Bi, Chaoyue Zheng and Xiaohu Zheng*. Increased expression of adenosine A3 receptor in tumor-infiltrating natural killer cells. Cell Mol Immunol. 2021, DOI: 10.1038/s41423-020-00632-1. (IF=11.531).
[12] Xiaohu Zheng, Haiming Wei*. Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment. 2021, Front Oncol, DOI: 10.3389/fonc.2021.628243. (IF=6.242).
[17] Xiaohu Zheng , Fan X, Fu B, Zheng M, Zhang A, Zhong K, Yan J, Sun R, Tian Z*, Wei H*, EpCAM inhibition sensitizes chemoresistant leukemia to immune surveillance. Cancer Research, JAN 15 2017, 77; 482-493. (IF=12.703).
[15] Xiaohu Zheng, Yeben Qian, Binqing Fu, Defeng Jiao, Yong Jiang, Peng Chen, Yiqing Shen, Huafeng Zhang, Rui Sun, Zhigang Tian* and Haiming Wei *, Mitochondrial fragmentation limits natural killer cell-based tumour immunosurveillance. Nature Immunology, 2019 Dec, 20;1656-1667. (IF=25.6).
[13] Yonggang Zhou#; Binqing Fu#; Xiaohu Zheng#; Dongsheng Wang; Changcheng Zhao; Yingjie qi; Rui Sun; Zhigang Tian; Xiaoling Xu*; Haiming Wei*. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. National Science Review. 2020, DOI:10.1093/nsr/nwaa041. (IF=17.275).
[19] Xiaohu Zheng, Zhigang Tian, Haiming Wei*. Lung specific X protein as a novel therapeutic target for lung cancer. OncoImmunology, 2015 Aug 17;4(12):e1052931. (IF=8.114).
[14] Xin Zhang, Dong Wang, Zhidong Li, Defeng Jiao, Linlin Jin, Jingjing Cong, Xiaohu Zheng* and Lijun Xu*. Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer. Front Immunol, Feb 2020, Volume 11. (IF=7.562).
[20] Zheng Xiaohu,Zheng Xiaohu.Targeting LUNX Inhibits Non-Small Cell Lung Cancer Growth and Metastasis.CANCER RESEARCH,2015,75(6):1080-1090.
[18] Xiaohu Zheng, Min Cheng, Binqing Fu, Xiaolei Fan, Qing Wang, Xiaoqing Yu, Rui Sun, Zhigang Tian*, Haiming Wei*. Targeting LunX inhibits non-small-cell lung cancer growth and metastasis. Cancer Research, March 15, 2015 75; 1080-90. (IF=12.533).
[16] Yong Jiang#, Xiaohu Zheng#, Defeng Jiao, Peng Chen, Yechuan Xu, Haiming Wei*, Yeben Qian*. Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma. EBioMedicine, 2019 Feb;40:422-431. (IF=8.141).

total21 2/3

first previous next last Page